Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35551582.
- Also identified by DOI 10.1001/jamaoncol.2022.1167 and PMC identifier 9100455.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines rates of gene testing in patients with urothelial cancer, uptake of gene-targeted therapy with erdafitinib, and overall survival outcomes.
Medical subject headings
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms